MedKoo Cat#: 405580 | Name: ZM306416
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ZM306416 is a selective antagonist of the vascular endothelial growth factor receptor-2 (VEGFR-2), which plays a crucial role in angiogenesis. It inhibits VEGF-induced receptor activation and downstream signaling, thereby suppressing endothelial cell proliferation, migration, and new blood vessel formation. This mechanism makes it a valuable compound in cancer research, particularly for studying anti-angiogenic therapies aimed at limiting tumor vascularization. Additionally, ZM306416 has potential applications in ophthalmic diseases like age-related macular degeneration, where pathological angiogenesis contributes to disease progression.

Chemical Structure

ZM306416
ZM306416
CAS#690206-97-4 (free base)

Theoretical Analysis

MedKoo Cat#: 405580

Name: ZM306416

CAS#: 690206-97-4 (free base)

Chemical Formula: C16H13ClFN3O2

Exact Mass: 333.0680

Molecular Weight: 333.74

Elemental Analysis: C, 57.58; H, 3.93; Cl, 10.62; F, 5.69; N, 12.59; O, 9.59

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 150.00 Ready to ship
50mg USD 250.00 Ready to ship
100mg USD 450.00 Ready to ship
200mg USD 750.00 Ready to ship
500mg USD 1,650.00 Ready to ship
1g USD 2,950.00 Ready to ship
2g USD 5,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
196603-47-1 (HCl) 690206-97-4 (free base)
Synonym
ZM306416; ZM 306416; ZM-306416
IUPAC/Chemical Name
4-[(4'-Chloro-2'-fluoro)phenylamino]-6,7-dimethoxyquinazoline
InChi Key
YHUIUSRCUKUUQA-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)
SMILES Code
COC1=CC2=NC=NC(NC3=CC=C(Cl)C=C3F)=C2C=C1OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Biological target:
ZM-306416 (CB 676475) is an inhibitor of VEGFR with IC50s of 0.1 and 2 μM for KDR and Flt, respectively.
In vitro activity:
The expression of primary alveolar osteoblast VEGF receptors and the subsequent effects on mineralization and nodule formation in vitro following VEGFR inhibition were investigated. The HAOBs (human alveolar osteoblasts) expressed high levels of VEGF and VEGFR1 protein but VEGFR2 was not detected. The VEGFR1/2 inhibitor, ZM306416, led to a dose-dependent decrease in mineralization. Reference: Aust Dent J. 2020 Sep;65(3):196-204. https://onlinelibrary.wiley.com/doi/10.1111/adj.12752
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 55.7 166.81
DMF 50.0 149.82
Ethanol 20.0 59.93
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 333.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. McLaughlin KI, Milne TJ, Zafar S, Zanicotti DG, Cullinan MP, Seymour GJ, Coates DE. The in vitro effect of VEGF receptor inhibition on primary alveolar osteoblast nodule formation. Aust Dent J. 2020 Sep;65(3):196-204. doi: 10.1111/adj.12752. Epub 2020 Mar 27. PMID: 32072641.
In vitro protocol:
1. McLaughlin KI, Milne TJ, Zafar S, Zanicotti DG, Cullinan MP, Seymour GJ, Coates DE. The in vitro effect of VEGF receptor inhibition on primary alveolar osteoblast nodule formation. Aust Dent J. 2020 Sep;65(3):196-204. doi: 10.1111/adj.12752. Epub 2020 Mar 27. PMID: 32072641.
In vivo protocol:
TBD
1: Pham TM, Ahmed M, Lai TH, Bahar ME, Hwang JS, Maulidi RF, Ngo QN, Kim DR. Regulation of Cell Cycle Progression through RB Phosphorylation by Nilotinib and AT-9283 in Human Melanoma A375P Cells. Int J Mol Sci. 2024 Mar 3;25(5):2956. doi: 10.3390/ijms25052956. PMID: 38474202; PMCID: PMC10932151. 2: Ye Q, Wang J, Ducatman B, Raese RA, Rogers JL, Wan YW, Dong C, Padden L, Pugacheva EN, Qian Y, Guo NL. Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer. Int J Mol Sci. 2023 Jun 23;24(13):10561. doi: 10.3390/ijms241310561. PMID: 37445737; PMCID: PMC10342177. 3: Ye Q, Hickey J, Summers K, Falatovich B, Gencheva M, Eubank TD, Ivanov AV, Guo NL. Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival. Int J Mol Sci. 2022 Nov 29;23(23):14978. doi: 10.3390/ijms232314978. PMID: 36499305; PMCID: PMC9738413. 4: Chang JH, Cheng CC, Lu YY, Chung CC, Yeh YH, Chen YC, Higa S, Chen SA, Chen YJ. Vascular endothelial growth factor modulates pulmonary vein arrhythmogenesis via vascular endothelial growth factor receptor 1/NOS pathway. Eur J Pharmacol. 2021 Nov 15;911:174547. doi: 10.1016/j.ejphar.2021.174547. Epub 2021 Oct 5. PMID: 34624234. 5: McLaughlin KI, Milne TJ, Zafar S, Zanicotti DG, Cullinan MP, Seymour GJ, Coates DE. The in vitro effect of VEGF receptor inhibition on primary alveolar osteoblast nodule formation. Aust Dent J. 2020 Sep;65(3):196-204. doi: 10.1111/adj.12752. Epub 2020 Mar 27. PMID: 32072641. 6: Wu WB, Xu YY, Cheng WW, Yuan B, Zhao JR, Wang YL, Zhang HJ. Decreased PGF may contribute to trophoblast dysfunction in fetal growth restriction. Reproduction. 2017 Sep;154(3):319-329. doi: 10.1530/REP-17-0253. Epub 2017 Jul 4. PMID: 28676532. 7: Fujimoto T, Inoue T, Maki K, Inoue-Mochita M, Tanihara H. Vascular Endothelial Growth Factor-A Increases the Aqueous Humor Outflow Facility. PLoS One. 2016 Sep 1;11(9):e0161332. doi: 10.1371/journal.pone.0161332. PMID: 27584577; PMCID: PMC5008796. 8: Antczak C, Mahida JP, Bhinder B, Calder PA, Djaballah H. A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. J Biomol Screen. 2012 Aug;17(7):885-99. doi: 10.1177/1087057112446174. Epub 2012 May 9. PMID: 22573732; PMCID: PMC3615554.